A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).
复制标题

DOI:
10.1007/s40273-020-00952-0
复制
发表时间:
2020-11
期刊:
影响因子:
4.4
通讯作者:
Di Tanna GL
Di Tanna GL
中科院分区:
医学2区
文献类型:
--
作者:
Urbich M;Globe G;Pantiri K;Heisen M;Bennison C;Wirtz HS;Di Tanna GL

文献摘要

参考文献

被引文献

相似文献

心力衰竭在美国带来了日益增长的临床和经济负担。关于疾病负担的可靠成本数据对于新治疗干预措施的经济评估至关重要。这项对美国心力衰竭相关费用的系统文献综述旨在评估已发表证据的质量并提供当前数据的叙述性综合。对四个电子数据库(MEDLINE、EMBASE、EconLit 以及约克评论和传播中心数据库,包括 NHS 经济评估数据库和健康技术评估数据库)检索了 2014 年 1 月至 2020 年 3 月期间发表的期刊文章。该综述已在 PROSPERO 注册(CRD42019134201),仅限于美国发生心力衰竭事件的成人的疾病成本研究。纳入了 87 项研究,其中 41 项可以对不同研究的成本估算进行比较。心力衰竭护理的年度总医疗费用中位数估计为每名患者 24,383 美元,其中心力衰竭特定的住院费用增加(每名患者中位数为 15,879 美元)。亚组分析显示,心力衰竭相关费用对患者个体特征(例如是否存在合并症和年龄)高度敏感,即使在亚组内也存在很大差异。此外,研究设计的差异和标准化报告的缺乏限制了比较成本估算的能力。与射血分数保留的患者相比,射血分数降低的心力衰竭患者的费用更高,这一发现凸显了区分不同心力衰竭类型的必要性。该审查支持了早期审查得出的结论,即住院费用是心力衰竭相关费用的主要驱动因素。子组分析可以更清楚地了解成本数据异质性的来源。虽然当前的成本估算提供了经济负担的有用指示,但了解数据的细微差别对于支持其应用至关重要。本文的在线版本 (10.1007/s40273-020-00952-0) 包含补充材料,可供授权用户使用。
Heart failure presents a growing clinical and economic burden in the USA. Robust cost data on the burden of illness are critical to inform economic evaluations of new therapeutic interventions. This systematic literature review of heart failure-related costs in the USA aimed to assess the quality of the published evidence and provide a narrative synthesis of current data. Four electronic databases (MEDLINE, EMBASE, EconLit, and the Centre for Reviews and Dissemination York Database, including the NHS Economic Evaluation Database and Health Technology Assessment Database) were searched for journal articles published between January 2014 and March 2020. The review, registered with PROSPERO (CRD42019134201), was restricted to cost-of-illness studies in adults with heart failure events in the USA. Eighty-seven studies were included, 41 of which allowed a comparison of cost estimates across studies. The annual median total medical costs for heart failure care were estimated at $24,383 per patient, with heart failure-specific hospitalizations driving costs (median $15,879 per patient). Analyses of subgroups revealed that heart failure-related costs are highly sensitive to individual patient characteristics (such as the presence of comorbidities and age) with large variations even within a subgroup. Additionally, differences in study design and a lack of standardized reporting limited the ability to compare cost estimates. The finding that costs are higher for patients with heart failure with reduced ejection fraction compared with patients with preserved ejection fraction highlights the need for differentiating among different heart failure types. The review underpins the conclusion drawn in earlier reviews, namely that hospitalization costs are the key driver of heart failure-related costs. Analyses of subgroups provide a clearer understanding of sources of heterogeneity in cost data. While current cost estimates provide useful indications of economic burden, understanding the nuances of the data is critical to support its application. The online version of this article (10.1007/s40273-020-00952-0) contains supplementary material, which is available to authorized users.
DOI: 10.1161/jaha.118.011089
发表时间: 2019-05-07
影响因子: 5.4
作者:
Albert, Nancy M.;Swindle, Jason P.;Chang, Chunlan
通讯作者: Chang, Chunlan
DOI: 10.1016/j.amjcard.2018.12.014
发表时间: 2019-03-15
影响因子: 2.8
作者:
Adejumo, Adeyinka Charles;Adejumo, Kelechi Lauretta;Adeboye, Adedayo
通讯作者: Adeboye, Adedayo
DOI: 10.1161/cir.0000000000000485
发表时间: 2017-03-07
期刊: Circulation
影响因子: 37.8
作者:
Benjamin EJ;Blaha MJ;Chiuve SE;Cushman M;Das SR;Deo R;de Ferranti SD;Floyd J;Fornage M;Gillespie C;Isasi CR;Jiménez MC;Jordan LC;Judd SE;Lackland D;Lichtman JH;Lisabeth L;Liu S;Longenecker CT;Mackey RH;Matsushita K;Mozaffarian D;Mussolino ME;Nasir K;Neumar RW;Palaniappan L;Pandey DK;Thiagarajan RR;Reeves MJ;Ritchey M;Rodriguez CJ;Roth GA;Rosamond WD;Sasson C;Towfighi A;Tsao CW;Turner MB;Virani SS;Voeks JH;Willey JZ;Wilkins JT;Wu JH;Alger HM;Wong SS;Muntner P;American Heart Association Statistics Committee and Stroke Statistics Subcommittee
通讯作者: American Heart Association Statistics Committee and Stroke Statistics Subcommittee
DOI: 10.1002/phar.1701
发表时间: 2016-02-01
期刊: PHARMACOTHERAPY
影响因子: 4.1
作者:
Bress, Adam P.;King, Jordan B.;Munger, Mark
通讯作者: Munger, Mark
DOI: 10.1016/j.amjcard.2017.05.058
发表时间: 2017-09-01
影响因子: 2.8
作者:
Akintoye, Emmanuel;Briasoulis, Alexandros;Levine, Diane
通讯作者: Levine, Diane